MedPath

Revogenex, Inc.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

1

Active:0
Completed:0

Trial Phases

1 Phases

Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 2
1 (100.0%)

A Four Arm Study to Evaluate the Safety and Efficacy of 3 Different Doses of RVX-100 Versus Placebo in Subjects With Irritable Bowel Syndrome Accompanied by Diarrhea (IBS-D)

Phase 2
Suspended
Conditions
Irritable Bowel Syndrome
Interventions
Drug: 0.075 mg RVX-100
Drug: 0.125 mg RVX-100
Drug: 0.250 mg RVX-100
Drug: placebo
First Posted Date
2010-02-26
Last Posted Date
2010-07-19
Lead Sponsor
Revogenex, Inc.
Target Recruit Count
192
Registration Number
NCT01076699
Locations
🇺🇸

Metropolitan Gastroenterology Group, Chevy Chase, Maryland, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.